Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial to Treat Multiple Myeloma, is Effective in Mod...

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE Amex: SNT), announced today that an oral presentation will be delivered at the 15th Annual Meeting of the American Society of Gene & Cell Therapy. The conference will be held May 16-19th, 2012 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The Company will present during the Cancer-Targeted Gene & Cell Therapy Oral Abstract Session, which will begin Thursday, May 17, at 1:15 P.M. Eastern Time. The oral presentation, entitled “SNS01-T, an eIF5A-Based Gene Therapy Nanoparticle Designed for the Treatment of Multiple Myeloma, has Anti-Tumoral Activity in Lymphoma”, will describe the effectiveness of SNS01-T in B-cell cancers, which is designed to selectively induce programmed cell death. The talk will be delivered by Catherine Taylor who is from Senesco CSO John Thompson’s research laboratory at the University of Waterloo in Ontario, Canada.

About Multiple Myeloma

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.

About Senesco Technologies, Inc.

Senesco, a leader in eIF5A technology, is running a clinical study in multiple myeloma with its lead therapeutic candidate SNS01-T, which targets B-cell cancers by selectively inducing apoptosis by modulating eukaryotic translation initiation factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ products. www.senesco.com

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the ability of the Company to consummate additional financings; the Company’s ability to recruit and enroll patients for its clinical trial;the development of the Company’s gene technology; the approval of the Company’s patent applications; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the Company’s ability to comply with the continued listing standards of the NYSE Amex, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.